These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 16243897

  • 1. Cytotoxicity of human RNase-based immunotoxins requires cytosolic access and resistance to ribonuclease inhibition.
    Erickson HA, Jund MD, Pennell CA.
    Protein Eng Des Sel; 2006 Jan; 19(1):37-45. PubMed ID: 16243897
    [Abstract] [Full Text] [Related]

  • 2. Angiogenin single-chain immunofusions: influence of peptide linkers and spacers between fusion protein domains.
    Newton DL, Xue Y, Olson KA, Fett JW, Rybak SM.
    Biochemistry; 1996 Jan 16; 35(2):545-53. PubMed ID: 8555226
    [Abstract] [Full Text] [Related]

  • 3. Recombinant antibody fragments and immunotoxin fusions for cancer therapy.
    Brinkmann U.
    In Vivo; 2000 Jan 16; 14(1):21-7. PubMed ID: 10757057
    [Abstract] [Full Text] [Related]

  • 4. Cloning and cytotoxicity of a human pancreatic RNase immunofusion.
    Zewe M, Rybak SM, Dübel S, Coy JF, Welschof M, Newton DL, Little M.
    Immunotechnology; 1997 Jun 16; 3(2):127-36. PubMed ID: 9237097
    [Abstract] [Full Text] [Related]

  • 5. Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma.
    Huhn M, Sasse S, Tur MK, Matthey B, Schinköthe T, Rybak SM, Barth S, Engert A.
    Cancer Res; 2001 Dec 15; 61(24):8737-42. PubMed ID: 11751393
    [Abstract] [Full Text] [Related]

  • 6. From immunotoxins to immunoRNases.
    De Lorenzo C, D'Alessio G.
    Curr Pharm Biotechnol; 2008 Jun 15; 9(3):210-4. PubMed ID: 18673286
    [Abstract] [Full Text] [Related]

  • 7. Antigen-specific targeting and elimination of EBV-transformed B cells by allergen toxins.
    Stöcker M, Klockenbring T, Huhn M, Nachreiner T, Wicklein D, Petersen A, Bauer R, Goerlich R, Fischer R, Barth S.
    J Allergy Clin Immunol; 2005 Oct 15; 116(4):910-5. PubMed ID: 16210069
    [Abstract] [Full Text] [Related]

  • 8. Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion protein.
    Krauss J, Arndt MA, Vu BK, Newton DL, Seeber S, Rybak SM.
    Biochem Biophys Res Commun; 2005 Jun 03; 331(2):595-602. PubMed ID: 15850802
    [Abstract] [Full Text] [Related]

  • 9. A novel human antitumor dimeric immunoRNase.
    Riccio G, Borriello M, D'Alessio G, De Lorenzo C.
    J Immunother; 2008 Jun 03; 31(5):440-5. PubMed ID: 18463541
    [Abstract] [Full Text] [Related]

  • 10. Construction and characterization of human CD7-specific single-chain Fv immunotoxins.
    Pauza ME, Doumbia SO, Pennell CA.
    J Immunol; 1997 Apr 01; 158(7):3259-69. PubMed ID: 9120282
    [Abstract] [Full Text] [Related]

  • 11. Cytotoxicity of bovine seminal ribonuclease: monomer versus dimer.
    Lee JE, Raines RT.
    Biochemistry; 2005 Dec 06; 44(48):15760-7. PubMed ID: 16313179
    [Abstract] [Full Text] [Related]

  • 12. Intracellular route and mechanism of action of ERB-hRNase, a human anti-ErbB2 anticancer immunoagent.
    De Lorenzo C, Di Malta C, Calì G, Troise F, Nitsch L, D'Alessio G.
    FEBS Lett; 2007 Jan 23; 581(2):296-300. PubMed ID: 17208233
    [Abstract] [Full Text] [Related]

  • 13. Improved stability and yield of Fv targeted superantigen by introducing both linker and disulfide bond into the targeting moiety.
    Hao HJ, Jiang YQ, Zheng YL, Ma R, Yu DW.
    Biochimie; 2005 Aug 23; 87(8):661-7. PubMed ID: 15927340
    [Abstract] [Full Text] [Related]

  • 14. Small cleavable adapters enhance the specific cytotoxicity of a humanized immunotoxin directed against CD64-positive cells.
    Hetzel C, Bachran C, Fischer R, Fuchs H, Barth S, Stöcker M.
    J Immunother; 2008 May 23; 31(4):370-6. PubMed ID: 18391759
    [Abstract] [Full Text] [Related]

  • 15. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
    Cao Y, Marks JD, Marks JW, Cheung LH, Kim S, Rosenblum MG.
    Cancer Res; 2009 Dec 01; 69(23):8987-95. PubMed ID: 19934334
    [Abstract] [Full Text] [Related]

  • 16. Chimeric fusion proteins--Pseudomonas exotoxin-based.
    Kreitman RJ.
    Curr Opin Investig Drugs; 2001 Sep 01; 2(9):1282-93. PubMed ID: 11717817
    [Abstract] [Full Text] [Related]

  • 17. Cytotoxic ribonucleases and chimeras in cancer therapy.
    Youle RJ, Newton D, Wu YN, Gadina M, Rybak SM.
    Crit Rev Ther Drug Carrier Syst; 1993 Sep 01; 10(1):1-28. PubMed ID: 8472310
    [Abstract] [Full Text] [Related]

  • 18. Expression, purification, and refolding of a novel immunotoxin containing humanized single-chain fragment variable antibody against CTLA4 and the N-terminal fragment of human perforin.
    Wan L, Zeng L, Chen L, Huang Q, Li S, Lu Y, Li Y, Cheng J, Lu X.
    Protein Expr Purif; 2006 Aug 01; 48(2):307-13. PubMed ID: 16584889
    [Abstract] [Full Text] [Related]

  • 19. Sensitivity of human leukemia cells in exponential or stationary growth phase to anti-CD5 immunotoxins. Role of intracellular processing events.
    Chignola R, Anselmi C, Franceschi A, Pasti M, Candiani C, Tridente G, Colombatti M.
    J Immunol; 1994 Mar 01; 152(5):2333-43. PubMed ID: 7510743
    [Abstract] [Full Text] [Related]

  • 20. Expression and characterization of bryodin 1 and a bryodin 1-based single-chain immunotoxin from tobacco cell culture.
    Francisco JA, Gawlak SL, Miller M, Bathe J, Russell D, Chace D, Mixan B, Zhao L, Fell HP, Siegall CB.
    Bioconjug Chem; 1997 Mar 01; 8(5):708-13. PubMed ID: 9327135
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.